Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab Adjuvant Therapy for Cervical Cancer
NCT06128460Phase 2Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of zimberelimab in Cervical Cancer (CC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06128460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128460.